Creating new drugs to fight bacterial toxins using probiotic yeast
Brewing anti-toxin drugs using probiotic yeast
['FUNDING_OTHER'] · NORTH CAROLINA STATE UNIVERSITY RALEIGH · NIH-10687670
This study is looking at a new way to help people with gut infections, like C. difficile, by using special yeast to create helpful substances that work with antibiotics to fight off bad bacteria and keep your gut healthy.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTH CAROLINA STATE UNIVERSITY RALEIGH (nih funded) |
| Locations | 1 site (RALEIGH, UNITED STATES) |
| Trial ID | NIH-10687670 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative drugs that can neutralize harmful toxins produced by bacteria in the gut. By using probiotic yeast, the project aims to create peptides that can work alongside antibiotics to enhance their effectiveness and reduce the risk of recurrent infections, such as those caused by C. difficile. The approach involves engineering these peptides to target specific toxin activities, which could help protect the beneficial bacteria in the gut while treating infections. Patients may benefit from a new treatment option that addresses antibiotic resistance and improves gut health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from recurrent bacterial infections, particularly those related to antibiotic resistance or C. difficile.
Not a fit: Patients with infections that do not involve bacterial toxins or those who are not affected by antibiotic resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with a new class of drugs that effectively combat bacterial infections while preserving healthy gut bacteria.
How similar studies have performed: While the approach of using probiotic yeast to develop anti-toxin therapies is innovative, similar strategies targeting bacterial toxins have shown promise in preliminary studies.
Where this research is happening
RALEIGH, UNITED STATES
- NORTH CAROLINA STATE UNIVERSITY RALEIGH — RALEIGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CROOK, NATHAN C. — NORTH CAROLINA STATE UNIVERSITY RALEIGH
- Study coordinator: CROOK, NATHAN C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Bacterial Infections, bacteria infection, bacterial disease, Disease